Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study-Reference-Cited by-同舟云学术

Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study

Published:2021-08 Issue:2 Volume:75 Page:439-441
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Wang Jitao,Hou Zhiyun,Liu Jianxin,Gu Ye,Wu Yunhong,Chen Zhenhuai,Ji Jiansong,Diao Shiqi,Qiu Yuanwang,Zou Shengqiang,Zhang Aiguo,Zhang Nina,Wang Fengxian,Li Xue,Wang Yan,Liu Xing^ORCID,Lv Cheng^ORCID,Chen Shubo,Liu Dengxiang,Ji Xiaolin,Liu Chao,Ren Tao,Sun Jingwei,Zhao Zhongwei,Wu Fazong,Li Fenxiang,Wang Ruixu,Yan Yan,Zhang Shiliang,Ge Guohong,Shao Jiangbo,Yang Shiying,Liu Chuan,Huang Yifei,Xu Dan,Li Xiaoguo,Ai Jingwen,He Qing,Zheng Ming-Hua,Zhang Liting,Xie Qing,Rockey Don C.,Fallowfield Jonathan A.^ORCID,Zhang Wenhong,Qi Xiaolong^ORCID

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Hepatology

Reference10 articles.

1. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients;Cornberg;J Hepatol,2021

2. Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study;Qi;Gut,2021

3. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes;Xia;JAMA,2020

4. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine;Polack;N Engl J Med,2020

5. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N Engl J Med,2021

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Absence of platelet overactivation and thrombosis formation among patients with coronary atherosclerosis disease after vaccination against SARS-CoV-2;2024-02-01

2. Inactivated vaccines reduce the risk of liver function abnormality in NAFLD patients with COVID-19: a multi-center retrospective study;eBioMedicine;2024-01

3. Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant;Hepatology Communications;2023-10-18

4. The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands;Expert Opinion on Drug Safety;2023-10-05

5. Immunogenicity and safety of a booster COVID‐19 vaccination in patients with chronic liver disease: A multicenter study;Portal Hypertension & Cirrhosis;2023-09